Mochi Health vs Medvi: Insurance Support and Cash-Pay Compared

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Medvi or Mochi Health, and no affiliate links or compensation are involved.

The clearest split between Mochi Health and Medvi is how they answer the cost question. Mochi leans on insurance-support workflows; Medvi runs a cash-pay compounded program. For anyone deciding between them, coverage strategy is the deciding variable — and it is worth understanding before the biology, not after. Both are among dozens of GLP-1 telehealth options as of April 2026.

Two different answers to the cost question

Insurance-support and cash-pay are two roads to the same medications. One tries to route your GLP-1 through a benefit and absorb some of the paperwork on your behalf; the other prices the medication directly and skips the claims process altogether. Which fits you depends on your plan, whether it covers weight-management therapy at all, your deductible, and your tolerance for prior-authorization steps that can stall or fail regardless of how well a program supports you.

Mochi Health and the insurance-support route

Mochi Health (Mochi) operates as telehealth plus insurance support: virtual clinical evaluation, provider-issued prescriptions, and help navigating coverage for GLP-1 therapy where a plan allows it, alongside compounded options through licensed pathways. Program and coverage specifics are posted at Mochi Health's official website. Coverage outcomes still depend on your individual insurance plan.

Medvi and the cash-pay compounded route

Medvi (Medvi Wellness) runs a telehealth-plus-compounded-pharmacy program that prices medication directly rather than routing it through insurance. Its terms are posted on Medvi's official website. Across cash-pay programs in this category, monthly totals commonly fall in the $200—$700+ range once evaluation, medication, and dispensing are combined.

Why the coverage path doesn't change the molecule

Whether a GLP-1 arrives via a benefit or a cash-pay order, the pharmacology is identical. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite, satiety, and gastric emptying, supported by STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Coverage strategy changes who pays and how much paperwork sits between you and a refill, not what the molecule does once it reaches you.

The genetic starting point neither route covers

No benefit check reads your genetics. Variants in FTO, GLP1R (the target of every GLP-1 compound), MC4R, and TCF7L2 shape the appetite and glucose-handling baseline a protocol works from. They are pathway-level, not predictors of any single drug response, yet they add context no coverage path provides. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across those genes.

How PlexusDx approaches the same decision

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — with a genetic read that no insurance workflow includes. Whichever way you settle the coverage question, that upstream context travels with you into the conversation with your provider.

Not affiliated: PlexusDx has no commercial ties to Medvi or Mochi Health and was not compensated for this review.

Related reading on PlexusDx: GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone.

Disclaimer: This article is educational. PlexusDx is not affiliated with Medvi or Mochi Health and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Frequently Asked Questions

Does Mochi Health take insurance for GLP-1 medication?

Mochi Health operates with insurance-support workflows, meaning it helps navigate coverage where your plan allows GLP-1 therapy, alongside compounded options. Whether a specific medication is covered depends entirely on your individual plan. Confirm current details and coverage steps on Mochi Health's own website.

Is cash-pay through Medvi cheaper than using insurance?

It depends on your plan. Cash-pay compounded programs like Medvi skip claims but price medication directly, while insurance-support routes may lower cost if your plan covers GLP-1 therapy. The comparison hinges on your specific coverage, so check both paths before deciding.

Does the genetic test affect insurance coverage?

No. The Precision Peptide Genetic Test is unrelated to coverage decisions and does not predict medication response. It maps pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 to give you baseline biological context to discuss with a provider, independent of how you pay.

How does PlexusDx compare on cost and context?

PlexusDx is a cash-pay program that adds an upstream genetic read most services skip. Rather than focusing only on coverage paperwork or the lowest headline rate, it pairs semaglutide and tirzepatide with pathway-level insight on FTO, GLP1R, and MC4R to inform the decision before you commit.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education